Nova Flu Pad 902 vaccine has been developed based on the Avian Influenza viruses currently circulating in Iran and the Middle East region, providing maximum antigenic similarity to the prevailing pathogenic field strains. This product contains a minimum of log₂ HAU 9 of inactivated (killed) Avian Influenza Virus subtype H9N2, capable of stimulating adequate antibody formation against Avian Influenza viruses after vaccination and inducing active immunity against Influenza Type A (H9N2).
The vaccine, formulated with an oil‑based adjuvant, acts as a strong inducer of antibody production and is stable, low‑viscosity, and easy to administer.